Man Group PLC Biovie Inc. Transaction History

Man Group PLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	SELL	$4.89 - $10.53 $20,826 - $44,847	-4,259 Reduced 23.21%	14,088 $113,000
Q4 2022 Feb 14, 2023	BUY	$3.86 - $42.0 $70,819 - $770,574	18,347 New	18,347 $142,000

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $34.4M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.